Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Argentina, Austria, Belgium, Brazil, Czechia, France, India, Israel, Italy, Japan, Mexico, Poland, Spain, Türkiye, and United Kingdom59 sites in 15 countriesChoose a country to see its sites
- Trial code
- NCT04088396
- EU 2023-507883-38-00
- EudraCT 2017-004495-60
- U1111-1302-1812
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 58 people, planned
- Started
- 12 Feb 2020
- Ended
- Oct 2026
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Baricitinib
- Tocilizumab
- Record updated
- 11 August 2026
Who can take part
- Age
- 1 year to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years
- Participants must have at least 2 active joints at screening and baseline
- Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age
- Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age
Who cannot take part
- Participants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis
- Participants must not have a current or recent (<4 weeks prior to baseline) clinically serious infection
- Participants must not have a history or presence of any autoimmune inflammatory condition other than JIA
- Participants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study
- Participants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks
- Participants must not have a positive test for hepatitis B virus
- Participants must not have evidence of active tuberculosis (TB) or untreated latent TB
- Participants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis
- Participants must not have persistent oligoarticular arthritis as defined by the ILAR criteria
Where is this trial?
It has sites in 15 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.
The 3 groups in the trial
- Cohort 1 BaricitinibTreatment being tested
Baricitinib given orally.
Treatment: Baricitinib
- Cohort 1 TocilizumabExisting treatment, for comparison
Tocilizumab given Subcutaneously (SC).
Treatment: Tocilizumab
- Cohort 2 BaricitinibTreatment being tested
Baricitinib given orally.
Treatment: Baricitinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.
- Record updated
- 11 August 2026